Solid Biosciences
SLDB
6.85
-0.07
-1.01%
Solid Biosciences
US · SLDB
#3476 by market cap
Listed 2018
6.85
-0.07
-1.01%
Live - 5344 symbols - heartbeat 273s ago
· 2026-10-08 09:04
Pre-market
6.73
-1.75%
After-hours
6.85
0.00%
Overnight
6.87
+0.29%
- Market cap
- 734.49M
- P/E (TTM)i
- -3.62
- P/Bi
- 1.96
- EPSi
- -1.99
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on SLDB?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 8 years
Margins
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 13.62M | 8.09M | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 17.72M | 24.58M | 21.58M | 27.14M | 28.95M | 27.75M | 33.30M | 38.88M |
| Research & development | 57.97M | 94.74M | 64.88M | 58.74M | 78.42M | 76.56M | 96.43M | 140.33M |
| Operating profit | -75.69M | -119.32M | -86.46M | -72.25M | -99.27M | -104.32M | -129.73M | -179.21M |
| Pretax profit | -74.80M | -117.22M | -88.29M | -72.19M | -85.98M | -96.02M | -124.70M | -174.33M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -74.80M | -117.22M | -88.29M | -72.19M | -85.98M | -96.02M | -124.70M | -174.33M |
| Basic EPS | -34 | -44 | -26 | -10 | -10 | -5 | -3 | -2 |
| Diluted EPS | -33.75 | -43.65 | -25.50 | -10.14 | -10.10 | -4.83 | -3.06 | -1.99 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | -- | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 9.14M | 9.28M | 9.20M | 11.27M | 11.17M | 13.12M |
| Research & development | 30.91M | 32.42M | 38.86M | 38.14M | 46.14M | 44.27M |
| Operating profit | -40.05M | -41.69M | -48.06M | -49.40M | -57.31M | -57.38M |
| Pretax profit | -39.28M | -39.48M | -45.78M | -49.79M | -56.74M | -54.80M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -39.28M | -39.48M | -45.78M | -49.79M | -56.74M | -54.80M |
| Basic EPS | -1 | 0 | 0 | -1 | -1 | 0 |
| Diluted EPS | -0.59 | -0.42 | -0.48 | -0.53 | -0.52 | -0.38 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 128.64M | 86.30M | 158.90M | 222.61M | 219.64M | 129.73M | 157.30M | 205.46M |
| Cash & ST investments | 122.46M | 83.52M | 154.74M | 207.78M | 213.72M | 123.64M | 148.92M | 187.85M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 139.60M | 103.47M | 171.17M | 232.38M | 260.25M | 164.94M | 188.66M | 232.54M |
| Total current liabilities | 12.48M | 18.28M | 24.48M | 23.60M | 22.51M | 14.52M | 30.26M | 33.47M |
| Short-term debt | 173.00K | 1.92M | 2.21M | 1.50M | 2.57M | 2.32M | 3.02M | 2.10M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 14,414,000.00 | 23,423,000.00 | 39,083,000.00 | 24,169,000.00 | 48,586,000.00 | 38,458,000.00 | 51,416,000.00 | 52,530,000.00 |
| Total equity | 125.18M | 80.05M | 132.09M | 208.21M | 211.67M | 126.48M | 137.25M | 180.01M |
| Retained earnings | -199.06M | -316.28M | -404.57M | -476.76M | -562.74M | -658.75M | -783.45M | -957.78M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 313.41M | 278.64M | 244.85M | 205.46M | 396.79M | 395.11M |
| Cash & ST investments | 306.92M | 268.11M | 236.14M | 187.85M | 380.68M | 377.68M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 343.90M | 308.29M | 273.91M | 232.54M | 422.89M | 420.58M |
| Total current liabilities | 28.78M | 29.85M | 36.34M | 33.47M | 30.28M | 28.58M |
| Short-term debt | 2.96M | 2.90M | 2.31M | 2.10M | 2.19M | 2.23M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 49,441,000.00 | 50,001,000.00 | 55,966,000.00 | 52,530,000.00 | 48,761,000.00 | 46,505,000.00 |
| Total equity | 294.46M | 258.29M | 217.95M | 180.01M | 374.13M | 374.08M |
| Retained earnings | -822.73M | -862.21M | -907.99M | -957.78M | -1.01B | -1.07B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -70.20M | -92.71M | -56.60M | -77.76M | -97.98M | -94.18M | -100.01M | -156.29M |
| Depreciation & amortization | 1.57M | 2.82M | 3.92M | 2.96M | 2.41M | 2.58M | 2.46M | 1.64M |
| Free cash flow | -77.97M | -97.10M | -57.50M | -79.05M | -100.99M | -95.70M | -100.67M | -157.44M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 133.69M | 49.33M | 132.49M | 134.88M | 72.55M | 2.97M | 122.12M | 194.74M |
| Ending cash balance | 86.69M | 76.37M | 155.07M | 121.21M | 157.22M | 75.85M | 82.19M | 61.89M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -31.85M | -37.41M | -33.47M | -53.56M | -47.23M | -52.59M |
| Depreciation & amortization | 407.00K | 386.00K | 376.00K | 467.00K | 395.00K | 391.00K |
| Free cash flow | -31.98M | -37.79M | -33.56M | -54.12M | -47.40M | -52.74M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 189.86M | -1.66M | 1.42M | 5.12M | 239.01M | 48.12M |
| Ending cash balance | 212.60M | 140.86M | 63.29M | 61.89M | 298.45M | 160.74M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -226.92 | -114.24 | -83.24 | -42.43 | -40.96 | -56.79 | -94.57 | -109.90 |
| ROA %i | -69.32 | -96.45 | -64.30 | -35.78 | -34.91 | -45.16 | -70.53 | -82.78 |
| ROIC %i | -221.85 | -111.38 | -78.81 | -41.58 | -39.33 | -52.50 | -85.19 | -101.73 |
| 5-year avg ROE %i | -- | -- | -- | -- | -101.55 | -67.53 | -63.60 | -68.93 |
| EBIT margin %i | -- | -- | -- | -530.50 | -1,226.51 | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 10.31 | 4.72 | 6.49 | 9.43 | 9.76 | 8.94 | 5.20 | 6.14 |
| Quick ratioi | 9.81 | 4.57 | 6.32 | 8.81 | 9.50 | 8.52 | 4.92 | 5.61 |
| Debt / assetsi | 0.74 | 6.83 | 3.01 | 0.89 | 10.97 | 15.92 | 12.82 | 9.10 |
| LT debt / equityi | 0.69 | 6.43 | 2.23 | 0.27 | 12.28 | 18.93 | 15.42 | 10.59 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -365.76 | -- |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | 0.00 | -- | -- | 0.00 | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -55.30 | -68.25 | -86.83 | -109.90 | -57.37 | -65.50 |
| ROA %i | -47.14 | -57.15 | -68.82 | -82.78 | -50.02 | -56.83 |
| ROIC %i | -53.54 | -65.34 | -82.07 | -101.73 | -56.57 | -64.31 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 10.89 | 9.34 | 6.74 | 6.14 | 13.10 | 13.82 |
| Quick ratioi | 10.66 | 8.98 | 6.50 | 5.61 | 12.57 | 13.21 |
| Debt / assetsi | 6.87 | 7.48 | 8.01 | 9.10 | 4.89 | 4.79 |
| LT debt / equityi | 7.02 | 7.80 | 9.00 | 10.59 | 4.94 | 4.79 |
| Interest coveragei | -445.25 | -539.65 | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing treatments through gene therapy and other means for patients with neuromuscular and100.00%
Region
United States100.00%
Quote time 2026-10-08 09:04:36 · For reference only, not investment advice and not tailored to your situation.